Key terms
About KA
Kineta, Inc. is a clinical-stage biotechnology company, which engages in the development of immunotherapies for cancer patients. Its pipeline includes immuno-suppression: aVISTA mAb and exhausted T-cells: aCD27 agonist mAb. The company was founded by Shawn P. Iadonato and Charles L. Magness in 2008 and is headquartered in Mercer Island, WA.
Sector
Industry
Employees
Founded
Website
Key stock statistics
1-day range
52-week range
Market cap
P/E ratio
Next earnings date
Dividend yield
Ex-dividend date
Dividend pay date
Key terms
Ad Feedback
Smart score
Latest KA news
Apr 08
4:12pm ET
Kineta Reports Progress in KVA12123 Cancer Trial
Apr 08
4:08pm ET
Kineta presents data from Phase 1/2 VISTA-101 clinical trial at AACR
Mar 12
8:27am ET
Kineta clears additional cohorts in Phase 1/2 VISTA-101 trial
Mar 12
8:22am ET
Kineta Explores Strategic Alternatives Amid Financial Struggles
Feb 29
8:35am ET
Kineta to reduce workforce by 64% in corporate restructuring
Feb 29
7:14am ET
Kineta Weighs Strategic Alternatives Amid Operational Challenges
Feb 22
8:32am ET
Kineta to present new preclinical data on KVA12123
Jan 23
4:50am ET
Analysts’ Opinions Are Mixed on These Healthcare Stocks: Kineta (KA), Gilead Sciences (GILD) and Evotec AG (EVO)
Jan 23
3:31am ET
Analysts Offer Insights on Healthcare Companies: Kineta (KA), Eli Lilly & Co (LLY) and Iovance Biotherapeutics (IOVA)
Jan 17
8:35am ET
Kineta provides update on ongoing Phase 1/2 VISTA-101 trial of KVA12123
No recent press releases are available for KA
KA Financials
Key terms
Ad Feedback
KA Forecasts
analyst rating
- buy
- hold
- sell
1-year stock price forecast
KA Competitors
$ Market cap
P/E ratio
$ Price
1d change
52-week range
